These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 17085151

  • 1. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.
    Green SA, Alon A, Ianus J, McNaughton KS, Tozzi CA, Reiss TF.
    J Urol; 2006 Dec; 176(6 Pt 1):2535-40; discussion 2540. PubMed ID: 17085151
    [Abstract] [Full Text] [Related]

  • 2. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
    Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S.
    J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
    Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, Hoel G.
    J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
    [Abstract] [Full Text] [Related]

  • 4. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
    Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, Wang J, Brodsky M, Bavendam T.
    J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
    [Abstract] [Full Text] [Related]

  • 5. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D, Cardozo L, Terpstra G, Bolodeoku J, Tamsulosin Study Group.
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist, in treating overactive bladder.
    Haab F, Braticevici B, Krivoborodov G, Palmas M, Zufferli Russo M, Pietra C.
    Neurourol Urodyn; 2014 Mar; 33(3):335-40. PubMed ID: 23765630
    [Abstract] [Full Text] [Related]

  • 7. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
    Steers WD, Herschorn S, Kreder KJ, Moore K, Strohbehn K, Yalcin I, Bump RC, Duloxetine OAB Study Group.
    BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
    [Abstract] [Full Text] [Related]

  • 8. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [Abstract] [Full Text] [Related]

  • 9. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG, Al-Buheissi S.
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [Abstract] [Full Text] [Related]

  • 10. Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
    Martínez-García R, Abadías M, Arañó P, Perales L, Ruíz JL, Sust M, Conejero J, ESCLIN 006/00 study group.
    Eur Urol; 2009 Jul; 56(1):184-90. PubMed ID: 18485575
    [Abstract] [Full Text] [Related]

  • 11. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
    Haab F, Stewart L, Dwyer P.
    Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
    [Abstract] [Full Text] [Related]

  • 12. Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.
    Chapple CR, Abrams P, Andersson KE, Radziszewski P, Masuda T, Small M, Kuwayama T, Deacon S.
    J Urol; 2014 Jan; 191(1):253-60. PubMed ID: 24018240
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
    Cardozo L, Khullar V, Wang JT, Guan Z, Sand PK.
    BJU Int; 2010 Sep; 106(6):816-21. PubMed ID: 20151972
    [Abstract] [Full Text] [Related]

  • 16. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J, SUNRISE Study Group.
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [Abstract] [Full Text] [Related]

  • 17. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z.
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [Abstract] [Full Text] [Related]

  • 18. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.
    Ohlstein EH, von Keitz A, Michel MC.
    Eur Urol; 2012 Nov; 62(5):834-40. PubMed ID: 22695239
    [Abstract] [Full Text] [Related]

  • 19. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
    Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stölzel M, Martin N, Gunther A, Van Kerrebroeck P.
    Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122
    [Abstract] [Full Text] [Related]

  • 20. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
    Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M.
    Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.